These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27751534)

  • 1. LRRK2 and the new era of Parkinson's disease research.
    The Lancet Neurology
    Lancet Neurol; 2016 Nov; 15(12):1195. PubMed ID: 27751534
    [No Abstract]   [Full Text] [Related]  

  • 2. LARGE-PD: Examining the genetics of Parkinson's disease in Latin America.
    Zabetian CP; Mata IF;
    Mov Disord; 2017 Sep; 32(9):1330-1331. PubMed ID: 28657124
    [No Abstract]   [Full Text] [Related]  

  • 3. Wild-type LRRK2 as a new potential therapeutic target in idiopathic Parkinson's disease.
    Sanjari Moghaddam H; Aarabi MH
    Mov Disord; 2018 Dec; 33(12):1876. PubMed ID: 30452792
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of LRRK2 Haplotype With Age at Onset in Parkinson Disease.
    Xiao B; Deng X; Ng EY; Allen JC; Lim SY; Ahmad-Annuar A; Tan EK
    JAMA Neurol; 2018 Jan; 75(1):127-128. PubMed ID: 29131875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enteric alpha-synuclein pathology in LRRK2-G2019S Parkinson's disease.
    Rouaud T; Clairembault T; Coron E; Neunlist M; Anheim M; Derkinderen P
    Parkinsonism Relat Disord; 2017 Jul; 40():83-84. PubMed ID: 28483388
    [No Abstract]   [Full Text] [Related]  

  • 6. Pathophysiological heterogeneity in Parkinson's disease: Neurophysiological insights from LRRK2 mutations.
    Kojovic M; Kassavetis P; Pareés I; Georgiev D; Rocchi L; Balint B; Foltynie T; Rothwell J; Bhatia K
    Mov Disord; 2017 Sep; 32(9):1333-1335. PubMed ID: 28686318
    [No Abstract]   [Full Text] [Related]  

  • 7. Leucine rich repeat kinase 2: a paradigm for pleiotropy.
    Lewis PA
    J Physiol; 2019 Jul; 597(14):3511-3521. PubMed ID: 31124140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 pathobiology in Parkinson's disease - virtual inclusion.
    Martin I; Kim JW; Dawson VL; Dawson TM
    J Neurochem; 2016 Oct; 139 Suppl 1():75-76. PubMed ID: 26899799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.
    Visanji NP; Bhudhikanok GS; Mestre TA; Ghate T; Udupa K; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kim S; Azhu Valappil R; Kausar F; Rogaeva E; William Langston J; Tanner CM; Schüle B; Lang AE; Goldman SM; Marras C
    Mov Disord; 2017 Apr; 32(4):610-614. PubMed ID: 28071824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of LRRK2 and GBA mutations in a Brazilian family with Parkinson's disease.
    Spitz M; Pereira JS; Nicareta DH; Abreu Gde M; Bastos EF; Seixas TL; Pimentel MM
    Parkinsonism Relat Disord; 2015 Jul; 21(7):825-6. PubMed ID: 25952961
    [No Abstract]   [Full Text] [Related]  

  • 11. LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease.
    Elbaz A
    Lancet Neurol; 2008 Jul; 7(7):562-4. PubMed ID: 18539536
    [No Abstract]   [Full Text] [Related]  

  • 12. LRRK2 mutations in Basque patients with Parkinson's disease.
    Zarranz JJ; Gómez-Esteban JC
    Lancet Neurol; 2008 Oct; 7(10):866-7; author reply 867. PubMed ID: 18848304
    [No Abstract]   [Full Text] [Related]  

  • 13. Occurrence of Crohn's disease with Parkinson's disease.
    Fujioka S; Curry SE; Kennelly KD; Tacik P; Heckman MG; Tsuboi Y; Strongosky AJ; van Gerpen JA; Uitti RJ; Ross OA; Ikezu T; Wszolek ZK
    Parkinsonism Relat Disord; 2017 Apr; 37():116-117. PubMed ID: 28215729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucine Rich Repeat Kinase 2: beyond Parkinson's and beyond kinase inhibitors.
    Cogo S; Greggio E; Lewis PA
    Expert Opin Ther Targets; 2017 Aug; 21(8):751-753. PubMed ID: 28609155
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study.
    Wang L; Heckman MG; Aasly JO; Annesi G; Bozi M; Chung SJ; Clarke C; Crosiers D; Eckstein G; Garraux G; Hadjigeorgiou GM; Hattori N; Jeon B; Kim YJ; Kubo M; Lesage S; Lin JJ; Lynch T; Lichtner P; Mellick GD; Mok V; Morrison KE; Quattrone A; Satake W; Silburn PA; Stefanis L; Stockton JD; Tan EK; Toda T; Brice A; Van Broeckhoven C; Uitti RJ; Wirdefeldt K; Wszolek Z; Xiromerisiou G; Maraganore DM; Gasser T; Krüger R; Farrer MJ; Ross OA; Sharma M;
    Neurobiol Aging; 2017 Jan; 49():217.e1-217.e4. PubMed ID: 27814993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of 2 induced pluripotent stem cell lines derived from patients with Parkinson's disease carrying LRRK2 G2385R variant.
    Cheng YC; Huang CY; Ho MC; Hsu YH; Syu SH; Lu HE; Lin HI; Lin CH; Hsieh PCH
    Stem Cell Res; 2018 Apr; 28():1-5. PubMed ID: 29414410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Parkinson's disease associated to mutation of the LRRK2 gene, mimicking multisystemic atrophy due to the combination of parkinsonism, early-onset dysautonomia and normal cardiac scintigraphy].
    Vilas D; Muxi A; Tolosa E; Compta Y
    Rev Neurol; 2016 Jul; 63(2):95-6. PubMed ID: 27377986
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic causes of PD: A pathway to disease modification.
    Toffoli M; Vieira SRL; Schapira AHV
    Neuropharmacology; 2020 Jun; 170():108022. PubMed ID: 32119885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations.
    Grisanti S; Ferri L; Cavallieri F; Fioravanti V; Vincenzi C; Toschi G; Grisendi I; Sabadini R; Paul JJ; Bauer P; Zedde M; Valzania F
    Mov Disord; 2022 May; 37(5):1117-1118. PubMed ID: 35587629
    [No Abstract]   [Full Text] [Related]  

  • 20. LRRK2 kinase in Parkinson's disease.
    Alessi DR; Sammler E
    Science; 2018 Apr; 360(6384):36-37. PubMed ID: 29622645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.